Clinical Trial Update: A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock [Phase 2]

View source ↗

Summary

Phase 2 study evaluating two doses of AZD9773 (CytoFab) in Japanese patients with severe sepsis or septic shock to assess safety and tolerability. Results have …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis
• Septic Shock

Drugs mentioned

• CytoFab (AZD9773)

Snippet

Sponsor: AstraZeneca | Conditions: Severe Sepsis, Septic Shock | Phase 2 | Status: COMPLETED | Results posted: 2013-08-22